Page 237 - 2019_05-HaematologicaMondo-web

GPIIb/IIIa peptide immunotherapy in HLA-transgenic mice
thrombocytopenic purpura. Transfus Apher
Sci. 2003;28(3):237-242.
18. Aslam R, Hu Y, Gebremeskel S, Segel GB, et
al. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood. 2012;120(10):2127-2132.
19. Elson CJ, Barker RN. Helper T cells in anti- body-mediated, organ-specific autoimmuni- ty. Curr Opin Immunol. 2000;12(6):664-669.
20. Barker RN, Vickers MA, Ward FJ. Controlling autoimmunity--lessons from the study of red blood cells as model antigens. Immunol Lett. 2007;108(1):20-26.
21. Hall AM, Ward FJ, Vickers MA, Stott LM, Urbaniak SJ, Barker RN. Interleukin-10- mediated regulatory T-cell responses to epi- topes on a human red blood cell autoanti- gen. Blood. 2002;100(13):4529-4536.
22. Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood. 2008;111(2):680- 687.
23. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocy- topenia. Blood. 2011;117(16):4190-4207.
24. Lozano ML, Revilla N, Gonzalez-Lopez TJ, et al. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guide- lines. Ann Hematol. 2016;95(7):1089-1098.
25. Frederiksen H, Maegbaek ML, Nørgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260-267.
26. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombo- cytopenia associated with the use of throm- bopoietin receptor agonists. Transfusion. 2013;53(11):2807-2812.
27. Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, Kuwana M. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytope- nia. Int J Hematol. 2014;100(4):341-344.
28. Larché M, Wraith DC. Peptide-based thera-
peutic vaccines for allergic and autoimmune
diseases. Nat Med. 2005;11(4 Suppl):S69-76. 29. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoim- mune and allergic diseases. Curr Opin
Immunol. 2010;22(5):609-615.
30. Hoffmann HJ, Valovirta E, Pfaar O, et al.
Novel approaches and perspectives in aller- gen immunotherapy. Allergy. 2017;72(7): 1022-1034.
31. Larché M. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc. 2014;11(Suppl 5):S292- 296.
32. Hirsch DL, Ponda P. Antigen-based immunotherapy for autoimmune disease: current status. Immunotargets Ther. 2014;4:1-11
33. Hall AM, Cairns LS, Altmann DM, Barker RN, Urbaniak SJ. Immune responses and tol- erance to the RhD blood group protein in HLA-transgenic mice. Blood. 2005;105(5): 2175-2179.
34. Hall LS, Hall AM, Pickford W, Vickers MA, Urbaniak SJ, Barker RN. Combination pep- tide immunotherapy suppresses antibody and helper T-cell responses to the RhD pro- tein in HLA-transgenic mice. Haematologica. 2014;99(3):588-596.
35. Shen CR, Youssef AR, Devine A, et al. Peptides containing a dominant T-cell epi- tope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood. 2003;102(10):3800-3806.
36. Negi RR, Bhoria P, Pahuja A, et al. Investigation of the possible association between the HLA antigens and idiopathic thrombocytopenic purpura (ITP). Immunol Invest. 2012;41(2):117-128.
37. Nomura S, Matsuzaki T, Ozaki Y, et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombo- cytopenic purpura. Blood. 1998;91(10):3616- 3622.
38. Bessos H, Perez S, Armstrong-Fisher S, Urbaniak S, Turner M. The development of a quantitative ELISA for antibodies against human platelet antigen type 1a. Transfusion. 2003;43(3):350-356.
39. Ellmerich S, Takacs K, Mycko M, et al. Disease-related epitope spread in a human- ized T cell receptor transgenic model of mul-
tiple sclerosis. Eur J Immunol.
2004;34(7):1839-1848.
40. Nishimura E, Sakihama T, Setoguchi R,
Tanaka K, Sakaguchi S. Induction of antigen- specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regu- latory T cells. Int Immunol. 2004;16(8):1189- 1201.
41. Devereux G, Hall AM, Barker RN. Measurement of T-helper cytokines secreted by cord blood mononuclear cells in response to allergens. J Immunol Methods. 2000;234(1-2):13-22.
42. Mackenzie KJ, Fitch PM, Leech MD, et al. Combination peptide immunotherapy based on T cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation. Immunology. 2013;138(3):258-268.
43. Gibson VB, Nikolic T, Pearce VQ, Demengeot J, Roep BO, Peakman M. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol. 2015;182(3):251- 260.
44. Nicolson KS, O'Neill EJ, Sundstedt A, Streeter HB, Minaee S, Wraith DC. Antigen- induced IL-10+ regulatory T cells are inde- pendent of CD25+ regulatory cells for their growth, differentiation, and function. J Immunol. 2006;176(9):5329-5337.
45. Goel G, King T, Daveson AJ, et al. Epitope- specific immunotherapy targeting CD4-pos- itive T cells in coeliac disease: two ran- domised, double-blind, placebo-controlled phase 1 studies. Lancet Gastroenterol Hepatol. 2017;2(7):479-493.
46. Alhadj Ali M, Liu YF, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new- onset type 1 diabetes. Sci Transl Med. 2017;9(402).pii:eaaf7779.
47. Singh H, Raghava GPS. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17(12):1236-1237.
48. Aslam R, Hu Y, Gebremeskel S, et al. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocy- topenia. Blood. 2012;120(10):2127-2132.
haematologica | 2019; 104(5)
1083